INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
oncodaily - The phase III INTerpath-001 trial demonstrated statistically significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) with the individualized mRNA-based neoantigen therapy intismeran plus pembrolizumab compare…
AI Summary: The INTerpath‑001 phase III trial reports positive results for a personalized mRNA neoantigen vaccine in high‑risk melanoma, demonstrating meaningful clinical benefit. Tailoring mRNA payloads to each patient’s tumor neoantigens produced robust anti‑tumor activity and improved outcomes, validating the personalized‑vaccine approach and giving precision immunotherapy its moment in the sun.
Related Stories
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 2 months
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 3 months
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 3 months
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 4 months
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 3 months
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 4 months
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Behavioral Health, Food Safety, Corporate Takeover, Novo Nordisk and look for the RSS link.
StackHealth Time Machine